Phase II evaluation of galactitol in head and neck cancer: A southwest oncology group study

Charles D. Haas, Daniel Lehane, Richard Bottomley

Research output: Contribution to journalArticle

Abstract

A phase II evaluation of DAG in head and neck cancer patients produced one partial response and one patient with prolonged stable disease from nine fully evaluable patients with squamous carcinomas. One partial response was produced in a patient with anaplastic thyroid carcinoma. No drug deaths or life-threatening toxicity were reported. Further evaluation of DAG in thyroid tumors is warranted.

Original languageEnglish (US)
Pages (from-to)281-283
Number of pages3
JournalMedical and Pediatric Oncology
Volume11
Issue number4
DOIs
StatePublished - 1983

Keywords

  • DAG
  • head and neck
  • phase II

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of galactitol in head and neck cancer: A southwest oncology group study'. Together they form a unique fingerprint.

Cite this